The short version of reconstitution fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Come What(ever) May is the second studio album by American rock band Stone Sour, released on August 1, 2006, by Roadrunner Records. It was recorded and produced by Nick Raskulinecz and the band at Studio 606 in Los Angeles, California. Writing for the album began as early as 2003 when vocalist Corey Taylor and guitarist James Root were writing material for their other band, Slipknot. In January 2006, Stone Sour began recording their second album, during which time drummer Joel Ekman left the band because of family constraints. He was eventually replaced by ex-Soulfly drummer Roy Mayorga who played on all but two tracks on the album. Following the release of the album, Stone Sour promoted it for over a year, releasing five singles and touring in the United States, Canada, Japan and several countries in Europe. The album received generally positive reviews. It was praised for showing a progression in the band's songwriting ability and musical style. It was also certified Platinum in the United States and the single "30/30-150" was nominated for Best Metal Performance at the 49th Grammy Awards. On June 26, 2007, Stone Sour released a special edition version of the album; it included six previously unreleased tracks and a bonus DVD with three music videos and a complete live performance by the band in Moscow. It remains their best-selling album to date, mostly due to the success of the single "Through Glass". The album became their first to be certified Platinum by the RIAA which occurred on July 21, 2017.
While genome annotation is primarily based on sequence similarity (and thus homology), other properties of sequences can be used to predict the function of genes. In fact, most gene function prediction methods focus on protein sequences as they are more informative and more feature-rich. For instance, the distribution of hydrophobic amino acids predicts transmembrane segments in proteins. However, protein function prediction can also use external information such as gene (or protein) expression data, protein structure, or protein–protein interactions. Evolutionary biology is the study of the origin and descent of species, as well as their change over time. Informatics has assisted evolutionary biologists by enabling researchers to:
== Oxygen-18 == Oxygen-18 (18O, Ω) is one of the stable isotopes of oxygen, with roughly 0.20% abundance, and considered one of the environmental isotopes. Most 18O is produced when 14N (made abundant from CNO burning) captures a 4He nucleus, becoming 18F. This quickly (half-life around 110 minutes) beta decays to 18O making that isotope common in the helium-rich zones of stars. Temperatures on the order of 109 kelvins are needed to fuse oxygen into sulfur. Fluorine-18 is usually produced by irradiation of 18O-enriched water with high-energy (about 18 MeV) protons prepared in a cyclotron or a linear accelerator, yielding an aqueous solution containing 18F as fluoride ion. This solution is then used for rapid synthesis of a labeled molecule, often with the fluorine atom replacing a hydroxy group. The labeled molecules or radiopharmaceuticals have to be synthesized after the radiofluorine is prepared, as the high energy proton radiation would destroy the molecules. Large amounts of oxygen-18 enriched water are used in positron emission tomography centers, for on-site production of 18F-labeled fluorodeoxyglucose (FDG). Measurements of the 18O/16O ratio (known as δ18O) are often used in paleoclimatology. Water molecules with a lighter isotope are slightly more likely to evaporate and less likely to fall as precipitation, so Earth's freshwater and polar ice have slightly less (0.1981%) 18O than air (0.204%) or seawater (0.1995%). This disparity allows the study of historical temperature patterns via the analysis of ice cores.
Physiologically, eating is generally triggered by hunger, but there are numerous physical and psychological conditions that can affect appetite and disrupt normal eating patterns. These include depression, food allergies, ingestion of certain chemicals, bulimia, anorexia nervosa, pituitary gland malfunction and other endocrine problems, and numerous other illnesses and eating disorders. A chronic lack of nutritious food can cause various illnesses, and will eventually lead to starvation. While changes in appetite can result from various physical and psychological conditions, including depression, allergies, and anxiety; anorexia and bulimia are specific eating disorders that profoundly impact the entire body. In anorexia nervosa, people restrict their calorie intake out of fear of gaining weight. This malnutrition leads to an unhealthy weight, significantly impacting overall health. Bulimia is characterized by recurrent episodes of binge eating, involving the consumption of a substantial amount of food within a short period. Subsequently, individuals engage in maladaptive behaviors, such as inducing vomiting, excessive physical activity, and using laxatives as compensatory measures. If eating and drinking is not possible, as is often the case when recovering from surgery, alternatives are enteral nutrition and parenteral nutrition.
== Mechanism == PNGase F catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. It cleaves all asparagine-linked complex, hybrid, or high mannose oligosaccharides unless the core GlcNAc contains an alpha 1,3- fucose. The asparagine residue, from which the glycan is removed, is deaminated to aspartic acid. PNGase F requires a minimum of two GlcNAc oligosaccharide residues attached to the asparagine in order for catalysis to occur. This enzyme utilizes a catalytic triad of cysteine-histidine-aspartate in its active site, which is a common motif for amidases. This motif contains a nucleophile, a proton donor, and a positive charge to stabilize the tetrahedral intermediate. The crystal structure of PNGase F from flavobacterium miningosepticum, with 1.8 Å resolution, was found to be folded in two domains, each with an eight-stranded antiparallel β barrel, or jelly roll, configuration. This structure is similar to lectins and glucanases, suggesting similarities with lectins and other carbohydrate-binding proteins.
Sources: en.wikipedia.org
=== Diagnosis and treatment === In current practice for dogs, B. canis is diagnosed using PCR, cultures, and serologic testing. The most standard test for B. canis is culture. These cultures are typically conducted on the host's blood, vaginal discharge, or semen. However, this method is not effective if the dog has been treated with antimicrobial drugs, as this will clear B. canis bacteria even if the disease has not resolved. Serology is used to evaluate the antibody response against Brucella spp. cell wall antigens, the downfall of this method is its lack of specificity. PCR testing has shown potential as a rapid test, however it is not readily available and is currently considered an experimental test. Currently, there are not commercially available vaccines for B. canis. Antimicrobial treatment and sterilization of the infected animals is considered an alternative to removing the animal. There have been reports of anti-Brucella vaccines (used for cattle and small ruminants), used along with previously mentioned methods but is not considered practical due to its risk of vaccine strain shedding in a domestic environment with current vaccines maintaining an amount of virulence for humans. Treatment for B. canis is very difficult to find and often very expensive. This is due to B. canis being a intracellular bacteria, meaning it replicates inside of host cells rather than outside of them. This makes it difficult for antibiotics to reach the bacteria.
== Research == As of August 2025, KNX-100 is in phase 2 clinical trials for treatment of agitation and aggression in dementia, phase 1 trials for opioid-related disorders and substance-related disorders, and the preclinical research stage of development for behavioral disorders. Phase 1 trials were first planned for 2019. Several clinical trials of KNX-100 have been registered with details provided. In addition to the preceding indications, there is also interest in KNX-100 for other potential applications like treatment of social anxiety, other types of addiction besides substance addiction like gambling, and pain, among others. Besides KNX-100, Kinoxis Therapeutics also has selective oxytocin receptor partial agonists like its KNX-200 series and oxytocin receptor positive allosteric modulators like its KNX-300/400 series in its developmental pipeline.
Manufactured cigarettes represent the most prevalent form of tobacco consumption globally, accounting for approximately 70% to 80% of all tobacco use. In addition to the inherent risks of tobacco use, manufactured cigarettes have specific engineering and chemical modifications that introduce secondary harms. Modern commercial cigarettes utilize filter ventilation (small perforations in the filter), which were historically marketed to reduce tar but actually encourage "compensatory smoking", where users inhale more deeply to maintain nicotine levels. The manufacturing process also incorporates approximately 600 additives, such as ammonia, which is used to "freebase" nicotine for faster absorption into the brain, and sugars that, when burned, produce the carcinogen acetaldehyde. Nearly all manufactured cigarettes in the U.S. and EU are classified as fire-safe cigarettes, which requires manufacturers to add chemicals to the paper to extinguish the cigarette if left unattended. Some studies and consumer reports have linked these treated papers to increased levels of carbon monoxide and naphthalene in the smoke, as well as unique side effects like increased respiratory irritation and headaches compared to other tobacco products.
The exiled mayor of occupied Melitopol, Ivan Fedorov reported an explosion in the city center which led to outages in water, telecommunications and electricity in the eastern and northern districts of the city as well as surrounding villages; pro-Russian authorities confirmed the explosion and the power outage. Novaya Gazeta reported that an improvised explosive device was planted in a rubbish bin near an apartment block where the Russian-installed acting "deputy minister" of construction and public utilities lived, which exploded and injured him when he exited the building.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.